Bispecific protein drives dual receptor degradation in mouse eye-disease models
Academic source · Proceedings of the National Academy of Sciences / PubMed
Source published: · Event / reporting date: 2026-11-04
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What the paper reports
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Why this paper is included
Analysis: The findings may broaden targeted degradation strategies for ocular disease, but comparative durability and safety still need validation beyond animal models.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections